Table 3.
Summary of the patients’ therapies and follow-up results
| Pat. no. | 177Lu- DOTATOC/ DOTATATE | Therapeutic activity (GBq) | Whole body residence time (h) | Maximum voxel activity (kBq)# | Lifetime in Tumor (h)§ | Maximum absorbed voxel dose (Gy) | Gy/GBq | EBRT target dose (Gy) | No. of fractions used for EBRT dose delivery | Change of EBRT dose due to PRRT (Gy) | Follow-up MR | Follow–up symptoms |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
DOTATOC |
7.0 |
39.3 |
71 |
72.4 |
4.0 |
0.57 |
60 |
30 |
0 |
No change |
Improvement of pituitary insufficiency,decreased vision unchanged |
| 2 |
DOTATOC |
7.3 |
19.1 |
277 |
29.7 |
6.6 |
0.90 |
48.6 |
27 |
−7 |
No change |
Retroorbital pressure fully resolved |
| 3 |
DOTATOC |
7.5 |
25.7 |
NA |
60.1 |
4.0* |
0.53 |
50 |
28 |
−4 |
No change |
Cranial nerve palsy fully resolved |
| 4 |
DOTATOC |
7.2 |
14.7 |
3 |
94.2 |
0.2 |
0.03 |
54 |
30 |
0 |
Complete remission |
Exophthalmus fully resolved |
| 5 |
DOTATOC |
7.6 |
17.1 |
191 |
44.0 |
6.7 |
0.88 |
54 |
30 |
0 |
No change |
Partial loss of vision, decresed general performance constant |
| 6 |
DOTATOC |
7.9 |
22.1 |
539 |
52.4 |
22.3 |
2.82 |
42 |
22 |
−11 |
No change |
Headache, hypesthesia improved |
| 7 |
DOTATATE |
7.9 |
27.2 |
557 |
68.2 |
30.7 |
3.89 |
60 |
30 |
0 |
No change |
Hemiparesis unchanged |
| 8 |
DOTATATE |
7.2 |
26.6 |
124 |
74.6 |
7.2 |
1.00 |
40 |
20 |
0 |
No change |
Paresis left leg unchanged |
| 9 |
DOTATATE |
7.3 |
32.3 |
305 |
69.6 |
16.6 |
2.27 |
54 |
30 |
0 |
Partial remission |
Epilepsy, tremor worsened, new hearing problems, resolved to pretherapeutic state after 2 months |
| 10 | DOTATATE | 7.4 | 32.5 | 161 | 64.8 | 8.2 | 1.11 | 52 | 20 | −6 | No change | Dizziness, ptosis constant |
# at 1 hour p.a. in 0.11 ³ voxel volume.
§ tumor residence time normalized to initial uptake.
* no SPECT/CT data available, value deduced from PET uptake.